<!doctype html><html lang="zh-hans"><head><meta charset="utf-8"><meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no"><title>FDA批准首次试验Crispr用于导致镰状细胞病的遗传缺陷 FDA approves first test of CRISPR for genetic defect causing sickle cell disease</title><link rel="stylesheet" href="https://stackpath.bootstrapcdn.com/bootstrap/4.3.1/css/bootstrap.min.css" integrity="sha384-ggOyR0iXCbMQv3Xipma34MD+dH/1fQ784/j6cY/iJTQUOhcWr7x9JvoRxT2MZw1T" crossorigin="anonymous"><link rel="stylesheet" href="/img/css.css?random="><link data-rh="true" rel="icon" href="/img/favicon.ico"/><script data-ad-client="ca-pub-6067137220025946" async src="https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js"></script><script type="text/javascript" src="https://platform-api.sharethis.com/js/sharethis.js#property=5effb96910009800120b8d4d&product=inline-share-buttons" async="async"></script>
<script>var _hmt = _hmt || [];(function() {var hm = document.createElement("script");hm.src = "https://hm.baidu.com/hm.js?03c1a0f31299b4a2fbb83c34d6beaac9";var s = document.getElementsByTagName("script")[0]; s.parentNode.insertBefore(hm, s);})();</script></head><body><div id="my_header"><div class="container"><nav class="navbar navbar-expand-lg"><a class="navbar-brand" href="/"><img alt="diglog" src="/img/logo.v1.gif" class="rounded-sm"></a><button class="navbar-toggler" type="button" data-toggle="collapse" data-target="#navbarNavAltMarkup" aria-controls="navbarNavAltMarkup" aria-expanded="false" aria-label="Toggle navigation"><span class="navbar-toggler-icon"></span></button><div class="collapse navbar-collapse" id="navbarNavAltMarkup"><div class="navbar-nav"></div></div></nav></div></div><div class="container"><div id="my_content"><h1 class="page_narrow">FDA approves first test of CRISPR for genetic defect causing sickle cell disease<br/>FDA批准首次试验Crispr用于导致镰状细胞病的遗传缺陷 </h1><div class="row"><div class="col-lg-12 col-12"><div class="my_story_list_item shadow p-3 mb-5 bg-white rounded"><div class="story_page_pub_time page_narrow">2021-04-08 08:47:23</div><div class="story_img_container"><a href="http://img2.diglog.com/img/2021/4/09a7a5edb5e68e498a6b8e62de544e78.jpg"><img src="http://img2.diglog.com/img/2021/4/09a7a5edb5e68e498a6b8e62de544e78.jpg" class="img-fluid my_story_img" onerror="this.style.display='none'"></a></div><div class="page_narrow text-break page_content"><p>In 2014, two years after her Nobel Prize-winning invention of CRISPR-Cas9 genome editing, Jennifer Doudna thought the technology was mature enough to tackle a cure for a devastating hereditary disorder, sickle cell disease, that afflicts millions of people around the world, most of them of African descent. Some 100,000 Black people in the U.S. are afflicted with the disease.</p><p>2014年，两年后，她的诺贝尔奖励胜利发明的CRISPR-CAS9 Genome编辑，Jennifer Doudna认为这项技术足够成熟，以解决一种治愈疣性疾病，镰状细胞疾病的治疗，这会让世界各地数百万人折磨其中大多数是非洲血统。美国的大约100,000名黑人患有这种疾病。</p><p> Mobilizing colleagues in the then-new Innovative Genome Institute (IGI) — a joint research collaboration between the University of California, Berkeley, and UC San Francisco — they sought to repair the single mutation that makes red blood cells warp and clog arteries, causing excruciating pain and often death. Available treatments today typically involve regular transfusions, though bone marrow transplants can cure those who can find a matched donor.</p><p> 调动当时的创新基因组研究所（IGI）的同事 - 加州大学，伯克利和UC旧金山之间的联合研究合作 - 他们试图修复一种使红细胞经线和堵塞动脉的单一突变，导致浮动痛苦和经常死亡。今天的可用治疗通常涉及定期输血，但骨髓移植可以治愈那些能找到匹配的捐赠者的人。</p><p> After six years of work, that experimental treatment has now been approved for clinical trials by the U.S. Food and Drug Administration, enabling the first tests in humans of a CRISPR-based therapy to directly correct the mutation in the beta-globin gene responsible for sickle cell disease. Beta-globin is one of the proteins in the hemoglobin complex responsible for carrying oxygen throughout the body.</p><p> 经过六年的工作，现已批准了美国食品和药物管理局的临床试验，使得基于Crispr的治疗的第一次测试能够直接纠正对镰刀的β-珠蛋白基因中的突变进行抑制细胞疾病。 β-珠蛋白是血红蛋白复合物中的蛋白质之一，其负责在整个体内携带氧气。</p><p> The trials, which are expected to take four years, will be led by physicians at UCSF Benioff Children’s Hospital Oakland and UCLA’s Broad Stem Cell Research Center who plan to begin this summer to enroll six adults and three adolescents with severe sickle cell disease.</p><p> 预计需要四年的审判将由UCSF贝尼夫儿童医院奥克兰和加州大学洛杉矶大学宽阔的干细胞研究中心的医生领导，他们计划从今年夏天开始六名成年人和三只具有严重镰状细胞疾病的成人和三名青少年。</p><p> The IGI’s clinical diagnostics laboratory, which was built under Doudna’s leadership to provide free COVID-19 testing to the Berkeley community, will play a key role in analytical support for the trial by developing diagnostics to monitor patient well-being and track the efficiency of the treatment.</p><p> IGI的临床诊断实验室是根据Doudna的领导地位建造的，为伯克利社区提供免费的Covid-19测试，将在通过开发诊断以监测患者福祉并追踪效率的诊断并跟踪效率的分析支持治疗。</p><p> “We are motivated to work toward a cure that can be accessible and affordable to patients worldwide,” said Doudna, UC Berkeley professor of molecular and cell biology and of chemistry and a Howard Hughes Medical Institute investigator. “The launch of this trial is an essential first step on that path.”</p><p> “我们有动力致力于在全球患者中可访问和负担得起的治疗方法，”UC伯克利分子和细胞生物学和化学教授和霍华德休斯医学研究所调查员Doudna说。 “这项试验的推出是该路径的重要第一步。”</p><p>  Other trials have successfully used CRISPR-Cas9 to knock out a gene that suppresses the fetal hemoglobin gene, which is normally turned off in humans. That technique reawakens the fetal gene and, in at least three patients, has alleviated symptoms of sickle cell disease.</p><p>  其他试验已经成功地使用CRISPR-CAS9敲出了抑制胎儿血红蛋白基因的基因，该基因通常在人体中关闭。该技术重新制备胎儿基因，在至少三名患者中，缓解了镰状细胞疾病的症状。 </p><p> The new trial is a gene knock-in: The researchers are using CRISPR-Cas9 to replace the defective beta-globin gene with a repaired version, with the goal of creating normal, adult red blood cells and curing the disorder.</p><p>新试验是一种基因敲门：研究人员正在使用CRISPR-CAS9用修复的版本取代缺陷的β-珠蛋白基因，目的是产生正常，成人红细胞并治愈这种疾病。</p><p> “This therapy has the potential to transform sickle cell disease care by producing an accessible, curative treatment that is safer than the current therapy of stem cell transplant from a bone marrow donor,” said Dr. Mark Walters, a professor of pediatrics at UCSF and principal investigator of the clinical trial and gene editing project. “If this is successfully applied in young patients, it has the potential to prevent irreversible complications of the disease.”</p><p> “这种疗法有可能通过生产比骨髓捐赠者的干细胞移植的当前治疗更安全的可接近的疗法治疗来改变镰状细胞病理护理，”UCSF教授Mark Walters博士说临床试验和基因编辑项目的主要研究人员。 “如果这是成功应用于年轻患者的，它有可能防止疾病的不可逆并发症。”</p><p> Another clinical trial also using CRISPR to directly correct the sickle cell mutation, but with a slightly different approach, is planned to begin this year, run by  Graphite Bio based on research out of Matthew Porteus’ lab at Stanford University.</p><p> 另一种临床试验还使用CRISPR直接纠正镰状细胞突变，但采用略有不同的方法，计划开始今年，基于Matthew Porteus'实验室在斯坦福大学的Matthew Porteus'实验室的石墨生物运行。</p><p>  The technique, as with the alternate approach that reawakens fetal hemoglobin, requires that some of the patient’s hematopoietic stem cells — the bone marrow cells that generate all the body’s red blood cells — be harvested for gene editing outside the body. After these cells are removed, the remaining bone marrow is destroyed with chemotherapy to allow space for the repaired and reinfused stem cells to grow.</p><p>  与重新制备胎儿血红蛋白的交替方法一样，该技术要求一些患者的造血干细胞 - 产生所有身体红细胞的骨髓细胞 - 被收获用于体内外部的基因编辑。除去这些细胞后，将剩余的骨髓与化疗破坏，以允许修复和再灌注干细胞生长的空间。</p><p>  Walters, who is also the Jordan Family Director of the Blood and Marrow Transplantation Program at UCSF Benioff Children’s Hospital Oakland, will be working with UCLA physician-scientist Dr. Donald Kohn, who has developed gene therapies for several genetic blood disorders, including a cure for a form of severe combined immunodeficiency (SCID). Kohn is also leading a  clinical trial of a different type of gene therapy for sickle cell disease, which involves adding a new gene to patients’ stem cells to overcome the sickle cell mutation.</p><p>  沃尔特斯也是UCSFBenioff儿童医院奥克兰血液和骨髓移植计划的约旦家庭总监，将与UCLA医师科学家Donald Kohn博士合作，他已经开发了几种遗传血液疾病的基因疗法，包括治愈方法出于严重组合免疫缺陷（SCID）的形式。 Kohn还领导着镰状细胞疾病不同类型的基因治疗的临床试验，这涉及向患者的干细胞添加新基因以克服镰状细胞突变。</p><p> “Gene therapy and gene editing allow each patient to serve as their own stem cell donor,” said Kohn, a distinguished professor of microbiology, immunology and molecular genetics, pediatrics, and molecular and medical pharmacology at the  David Geffen School of Medicine at UCLA and a member of the  UCLA Broad Stem Cell Research Center. “In theory, these approaches should be much safer than a transplant from another person and could become universally available because they eliminate the need to find the needle in a haystack that is a matched stem cell donor.”</p><p> “基因治疗和基因编辑允许每位患者作为自己的干细胞供体，”在大卫·佩芬医学院的微生物学，免疫学和分子遗传学，儿科教授，Pucla和Muffen医学院的分子和医学药理学教授kohn说UCLA宽松干细胞研究中心的成员。 “理论上，这些方法应该比另一个人的移植更安全，并且可能会普遍获得，因为它们消除了在作为匹配的干细胞供体中的干草堆中找到针的需要。”</p><p> Kohn will lead the laboratory and clinical trial activities at UCLA and oversee all manufacturing of the drug product, called CRISPR_SCD001, for the clinical trial. The preclinical work to develop this therapy was funded by the California Institute for Regenerative Medicine; the National Heart, Lung, and Blood Institute-led Cure Sickle Cell Initiative; and the Doris Duke Charitable Foundation.</p><p> Kohn将在UCLA领导实验室和临床试验活动，并监督所有称为CrisPr_SCD001的药品，用于临床试验。发展此疗法的临床前工作由加州再生医学研究所提供资金;全国心脏，肺和血液研究所 -  LED治愈镰状细胞倡议;和Doris Duke慈善基金会。 </p><p> Fyodor Urnov, IGI director of technology and translation and a UC Berkeley professor of molecular and cell biology, will oversee the bioinformatics and genomics activities for the study.</p><p>IGIOR Urnov，IGI技术和翻译总监以及分子和细胞生物学的UC伯克利教授将监督该研究的生物信息学和基因组学活动。</p><p> “It is noteworthy that this new trial comes from a consortium of not-for-profit academic institutions incentivized with a long-term vision to cure the disease with an affordable solution that can globally benefit everyone who needs it,” Urnov said.</p><p> “这是值得注意的是，这项新的审判来自于促进的非营利性学术机构的联盟，这是一种长期的愿景，以治愈这种疾病，这是一个可实惠的解决方案，可以全球受益于需要它的每个人，”乌尔诺夫说。</p><p>  Sickle cell disease is caused by a single change in the DNA code of the beta-globin gene. The new trial uses the CRISPR-Cas9 nuclease — a fully assembled Cas9 protein and guide RNA sequence targeting the defective region of the beta-globin gene, accompanied by a short DNA segment encoding the proper sequence — to stimulate repair of the sickle mutation by substituting the normal DNA segment for the abnormal one. In this approach, the patient’s blood stem cells are first treated with electrical pulses that create pores in their membranes. These pores allow the CRISPR-Cas9 platform to enter the stem cells and travel to their nuclei to correct the sickle cell mutation.</p><p>  镰状细胞疾病是由β-珠蛋白基因的DNA码中的单一变化引起的。新试验使用CRISPR-CAS9核酸酶 - 一个完全组装的CAS9蛋白和指向β-珠蛋白基因的缺陷区域的引导RNA序列，伴随着编码适当序列的短DNA段 - 通过代入刺激镰刀突变的修复异常的正常DNA段。在这种方法中，患者的血液干细胞首先用在其膜中产生孔的电脉冲处理。这些孔允许CRISPR-CAS9平台进入干细胞并向核来纠正镰状细胞突变。</p><p> “The goal of this form of genome-editing therapy is to correct the mutation in enough stem cells so the resulting blood in circulation has corrected red blood cells,” Walters said. “Based on our experience with bone marrow transplants, we predict that correcting 20% of the genes should be sufficient to out-compete the native sickle cells and have a strong clinical benefit.”</p><p> “这种形式的基因组编辑治疗的目标是校正足够干细胞中的突变，因此所得血液中的血液已经矫正红细胞，”沃尔特斯表示。 “根据我们对骨髓移植的经验，我们预测纠正20％的基因应该足以出去竞争镰状细胞并具有强烈​​的临床益处。”</p><p> The final manufacturing protocol uses a virus-free method to edit blood stem cells and has been validated in pre-clinical safety/toxicology studies performed after consultation with the FDA.</p><p> 最终制造协议使用无病毒方法来编辑血液干细胞，并已在与FDA咨询后进行的临床前安全/毒理学研究中验证。</p><p>  While UC physicians take the current CRISPR therapy into clinical trials, IGI scientists are working to improve the technique so that, eventually, the correction of the sickle cell mutation can be done inside the body, without removing stem cells or destroying the bone marrow. Because the bone marrow also produces white blood cells that protect us from disease, destroying it dampens the immune system and puts patients at increased risk of infection or even cancer until the infused, corrected stem cells can multiply and replenish.</p><p>  虽然UC医生将目前的CRISPR治疗患者进入临床试验，但IGI科学家正致力于改善技术，使得最终，镰状细胞突变的校正可以在体内进行，而不除去干细胞或破坏骨髓。因为骨髓也产生了保护我们免受疾病的白细胞，破坏它抑制免疫系统，并将患者提高感染风险或甚至癌症，直至注入矫正干细胞可以繁殖和补充。</p><p>  “Currently, we are doing ex vivo therapy, where you take cells out of the bone marrow to correct the mutation outside the body,” said Ross Wilson, IGI’s director of therapeutic delivery. “But during this time — it could be months — the bone marrow is filling back up. As a result, when it’s time to infuse the corrected cells, the patient must be subjected to aggressive chemotherapy that clears out the bone marrow and allows those corrected cells to find a home.”</p><p>  “目前，我们正在进行exvivo治疗，在那里服用细胞从骨髓中纠正身体外的突变，”IGI治疗性交付总监Ross Wilson说。 “但在这段时间里 - 可能是几个月 - 骨髓正在填补。结果，当它是注入校正的细胞时，必须对患者进行侵袭性化疗，以清除骨髓，并允许这些矫正细胞找到一个家庭。“ </p><p> Wilson is optimistic that he and IGI scientists can find a way to send the CRISPR therapy directly to the bone marrow inside the body, using antibodies to target the CRISPR enzyme to the correct stem cells. Other scientists, who use engineered viruses or fatty droplets — lipid nanoparticles — to ferry the CRISPR enzyme into the body, have so far failed.</p><p>威尔逊乐观地说，他和IGI科学家可以找到一种方法可以将CRISPR治疗直接送到身体内部的骨髓，使用抗体将CRISPR酶靶向正确的干细胞。其他科学家们使用工程化病毒或脂肪液滴 - 脂质纳米颗粒 - 将CRISPR酶交给身体，但到目前为止失败。</p><p> “The molecule we are trying to deliver is physically smaller — an eighth the diameter of the nanoparticles other people try to deliver to the bone marrow — and this could provide big benefits,” he said. “Our self-delivering enzyme should be able to reach the bone marrow.”</p><p> “我们试图提供的分子是物理上的 - 纳米颗粒的直径第八是其他人尝试送到骨髓 - 这可能提供大益处，”他说。 “我们的自我交付酶应该能够到达骨髓。”</p><p>  Whatever the successful strategy, either ex vivo or in vivo, the CRISPR platform developed for sickle cell disease could transform gene therapy for other diseases.</p><p>  无论是成功的策略，除了例如evivo还是体内，为镰状细胞疾病开发的CRISPR平台都可以转化其他疾病的基因治疗。</p><p> “That is the IGI vision: first sickle cell, but our efforts will have a ripple effect to enable cures for blood disorders in general, like beta thalassemia, as well as diseases of the immune system,” he said. “The hematopoietic stem cell is the seed for the entire immune system, so all blood disorders can theoretically be cured by a stem cell therapy like this.”</p><p> “这是IGI视觉：第一个镰状味道，但我们的努力将产生涟漪效应，使血液疾病的治疗通常，如β中西血症，以及免疫系统的疾病，”他说。 “造血干细胞是整个免疫系统的种子，因此所有血液障碍都可以通过这样的干细胞疗法治愈。” </p></div><div id="story_share_this"><div class="sharethis-inline-share-buttons"></div></div><div class="text-break sotry_link page_narrow"><a target="_blank" href="https://news.berkeley.edu/2021/03/30/fda-approves-first-test-of-crispr-to-correct-genetic-defect-causing-sickle-cell-disease/">https://news.berkeley.edu/2021/03/30/fda-approves-first-test-of-crispr-to-correct-genetic-defect-causing-sickle-cell-disease/</a></div><div class="story_tags page_narrow"><button type="button" class="btn btn-light my_tag"><a href="/tag/遗传/">#遗传</a></button><button type="button" class="btn btn-light my_tag"><a href="/tag/approves/">#approves</a></button><button type="button" class="btn btn-light my_tag"><a href="/tag/干细胞/">#干细胞</a></button></div></div><div class="my_movie_list_item shadow p-3 mb-5 bg-white rounded"><button type="button" class="btn btn-link my_tag"><a href="/tag/web2.0/">#web2.0</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/google/">#google</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/设计/">#设计</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/创意/">#创意</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/摄影/">#摄影</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/图片/">#图片</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/游戏/">#游戏</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/软件/">#软件</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/视频/">#视频</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/手机/">#手机</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/广告/">#广告</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/iphone/">#iphone</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/网站/">#网站</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/免费/">#免费</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/下载/">#下载</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/windows/">#windows</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/微软/">#微软</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/firefox/">#firefox</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/blog/">#blog</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/音乐/">#音乐</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/apple/">#apple</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/博客/">#博客</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/苹果/">#苹果</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/wordpress/">#wordpress</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/恶搞/">#恶搞</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/qq/">#qq</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/艺术/">#艺术</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/谷歌/">#谷歌</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/web/">#web</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/工具/">#工具</a></button></div></div></div><div id="my_footer"><div class=""><a href="/tags/">tags</a> <a href="/users/">users</a></div>&copy;2012-2021 diglog.com </div></div></body></html>